A5057727974- Pulmonary Hypertension Research and Treatments
- Asthma and respiratory diseases
- Inhalation and Respiratory Drug Delivery
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Coronary Interventions and Diagnostics
- Health and Well-being Studies
- Inflammatory mediators and NSAID effects
- Lipoproteins and Cardiovascular Health
- Acute Myocardial Infarction Research
Bayer (Germany)
2017-2018
Klinikum Ludwigshafen
2015
Summary Little is known about the onset of action after intravenous or oral administration acetylsalicylic acid (ASA) in patients with acute coronary syndromes (ACS). The aim study was to compare 250 500 mg 300 ASA naïve ACS concerning antiplatelet effects measured by time dependent thromboxane inhibition. A total 270 < 24 hours were randomised into one three treatment arms comprising a single dose as soon possible admission. primary endpoint platelet inhibition assessed measurement...
Inhaled iloprost is an effective therapy for patients with pulmonary arterial hypertension (PAH); however, some experience extended inhalation times when using the V10 formulation (10.0 µg/mL) to deliver a 5 -µg dose (at mouthpiece) and are at risk of incomplete inhalations reduced frequency. VENTASWITCH was observational, case-crossover study evaluate behavior in PAH switched from V20 (20.0 delivering I-Neb® AAD® device. Adults participating German Ventavis® (iloprost) patient-support...
Pulmonary arterial hypertension (PAH)-a progressive, ultimately fatal disease-patients often experience dyspnea, which can limit their daily physical activities. Iloprost is an inhaled therapy for PAH that has shown efficacy in clinical trials. However, trials have provided only limited data on activity. Digital monitoring of activity therefore attracting growing interest. To fully understand a patient's response to treatment, treatment adherence also required. The Breelib nebulizer...
Ventavis is an effective therapy for patients with PAH, improving exercise capacity and symptoms. nebuliser solution inhalation available as 10 µg/mL (V10) 20 (V20) formulations, administered using the I-Neb nebuliser. Some experience extended times V10 are at risk of incomplete inhalations reduced frequency. VENTASWITCH (NCT02826252) was a local, observational, case-crossover study behaviour in 64 PAH enrolled German patient support programme maintained on 5 μg dose switched from to V20....
Background: Current national and international guidelines recommend the use of oral and/or intravenous (IV) acetylsalicylic acid as an alternative mode application in patients with acute coronary syndrome (ACS) who are unable to swallow. However, IV has not been investigated clinical trials is available everywhere. Aim: The primary objective present open-label, randomized, verum-controlled, parallel-group, phase III study was demonstrate superiority 250 or 500 mg treatment over 300 tablet...
<sec> <title>BACKGROUND</title> Pulmonary arterial hypertension (PAH)—a progressive, ultimately fatal disease—patients often experience dyspnea, which can limit their daily physical activities. Iloprost is an inhaled therapy for PAH that has shown efficacy in clinical trials. However, trials have provided only limited data on activity. Digital monitoring of activity therefore attracting growing interest. To fully understand a patient’s response to treatment, treatment adherence also...